TSX Venture: QPT
EDMONTON, June 25 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or
the "Company"), today announced interim results from its Phase I/II clinical
study designed to investigate appropriate treatment parameters for the
potential use of its proprietary compound SL017 for hair removal applications.
The interim results represent data from the first 80 patients enrolled in the
targeted 100-patient clinical trial.
"The Phase I/II interim results demonstrated that SL017 is safe and well
tolerated when used either alone or in combination with photo activation,"
said Madi Madiyalakan, Chief Executive Officer of Quest. "These results, along
with results from the previous clinical trial, support the utility of SL017
for hair removal applications, especially for those who do not benefit from
light treatment alone."
To permanently remove unwanted hair, existing laser hair removal
techniques require four to eight treatments, and provide only a 75 to 85
percent permanent hair reduction in a limited patient population. The
professional laser hair removal market is estimated to be $5 billion
Quest is developing SL017 photodynamic therapy (PDT) as a potential hair
removal solution that is effective across a broad patient population including
those with light colored hair (for example, grey or blonde hair). In a Phase I
clinical trial, Quest demonstrated the preferential localization of SL017 in
hair follicles, which suggested that cutaneous PDT with SL017 has potential
for permanent hair removal applications.
The Phase I/II trial of SL017 was designed to evaluate the effect of skin
treatment on follicular uptake of SL017, assess the tolerable light dose on
healthy subjects, and subsequently, determine the efficacy of hair removal
under optimal treatment conditions. Results from this study will be used to
guide the design of future clinical development.
Skin Pretreatment and Follicular Uptake
Thirty healthy subjects were enrolled to evaluate the efficacy of five
different skin preparation techniques to enhance the follicular localization
of SL017. One of the five skin pretreatments demonstrated a statistically
significant improvement in both the intensity of follicular uptake of SL017
and the depth of penetration of SL017 in the hair follicle compared to the
other skin pretreatments.
Light Dose Escalation
Forty subjects with dark colored hair and 10 subjects with light colored
hair were enrolled to evaluate the safety and efficacy of combining SL017 with
increasing doses of Intense Pulse Light (IPL) ranging from 4.5J/cm(2) to
20.0J/cm(2). No skin pretreatment technique was used. No unexpected side
effects were observed at any of the light doses tested. A hair count was taken
at days 0 and 42 in each population. There was no statistically significant
improvement in hair count reduction observed in the subjects treated with
SL017 PDT compared to IPL treatment alone at any of the IPL doses or in either
of the two hair populations studied. However, 25% of the dark colored hair
population, or 10 subjects, that were non-responsive to IPL treatment
demonstrated a statistically significant reduction in hair count when treated
with SL017 PDT.
Hair Removal Efficacy Under Optimal Conditions
Quest is currently enrolling 20 additional patients, 10 with dark colored
hair and 10 with light colored hair, to evaluate the efficacy of SL017 PDT
compared to IPL at the optimal light dose and after skin pretreatment. The 20
subjects with light colored hair enrolled in the trial will also undergo two
SL017 PDT treatments. The hair growth of these patients will be monitored for
up to six months. Results from this part of the study are anticipated by end
"Based on the results we receive from these clinical studies in hair
removal and the preclinical work we are currently conducting for the treatment
of acne, we intend to advance SL017 PDT for one or more clinical indications,"
stated Thomas Woo, M.Sc., Vice President for Drug Development of Quest.
The Principal Investigator for Quest's Phase I/II hair removal trial is
Dr. Robert Bissonnette, M.D., President of Innovaderm Research in Montreal.
About SL017: SL017 is a proprietary, non-toxic drug that, once applied to
a target area and activated by light, is transformed into a potent cytotoxic
agent that selectively destroys targeted tissue. Using this process, known as
photodynamic therapy (PDT), SL017 can be applied to treat a variety of skin
conditions, including hair removal, actinic keratosis and acne. The safety and
potential utility of SL017 for the treatment of actinic keratosis has been
demonstrated in a Phase I Clinical Study.
About Quest PharmaTech Inc.: Quest is a publicly traded, Alberta-based
pharmaceutical company committed to the development and commercialization of
new pharmaceutical products. It is developing a series of products for the
treatment of cancer and dermatological conditions based on its unique
photodynamic and sonodynamic therapy platform.
"TSX Venture Exchange has neither approved nor disapproved of the
For further information:
For further information: Dr. Madi R. Madiyalakan, Chief Executive
Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email:
firstname.lastname@example.org, Internet: www.questpharmatech.com; Investor
Relations - Adam Peeler, The Equicom Group Inc., Tel: (416) 815-0700 Ext. 225,